The National Institute for Health and Care Excellence (NICE) approves the use of elranatamab as a fourth-line treatment for myeloma in England and WalesAccess, latest, MyelomaJuly 9, 2024
The European Commission grants final approval for elranatamab for the treatment of relapsed or refractory myelomaAccess, MyelomaDecember 8, 2023
Sign up for the MPE webinar on EHA myeloma and AL amyloidosis highlights AL amyloidosis, Conferences, MPE, MyelomaJune 14, 2023
MPE announces partnership in EU consortium project CERTAINTY: advancing cancer care through virtual twins in personalised immunotherapyMyelomaDecember 19, 2023
MPE launches the Myeloma and AL Amyloidosis European Clinical Trial NavigatorAccess, AL amyloidosis, MPE, MyelomaApril 23, 2024
European Commission approves CAR T-cell therapy ciltacabtagene autoleucel in earlier lines of therapy for relapsed and refractory myelomaAccess, CAR-T, MyelomaApril 23, 2024
New clinical trial to evaluate the myeloma drug selinexor as potential treatment for patients with COVID-19MyelomaApril 14, 2020
Ana Rocha, young myeloma patient: “I didn’t let the diagnosis change me and I thought I should build something to help others newly diagnosed”MPE, MyelomaMarch 8, 2024
Snežana Doder, young myeloma patient: “When I talk about my journey, I compare it to a roller coaster. Everything happened very fast and unexpectedly”MPE, MyelomaMarch 25, 2024
ASCO and EHA highlights in myeloma and AL amyloidosisAL amyloidosis, Conferences, MPE, Myeloma, VideosJuly 20, 2020
